Back to top
more

Eagle Pharmaceuticals (EGRX)

(Delayed Data from OTC)

$0.88 USD

0.88
9,005

+0.28 (45.83%)

Updated Oct 11, 2024 01:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Zacks.com featured highlights include Eagle Pharmaceuticals, Cabot, Meritage Homes, Griffon, and APA

Eagle Pharmaceuticals, Cabot, Meritage Homes, Griffon, and APA are part of Screen of the Week article.

Rimmi Singhi headshot

Press the Buy Button on These 5 High Earnings Yield Picks Now

One could invest in high earnings yield stocks like Eagle Pharmaceuticals (EGRX), Cabot (CBT), Meritage Homes (MTH), Griffon (GFF) and APA Corp (APA) to fetch handsome long-term rewards.

Eagle Pharmaceuticals (EGRX) Q1 Earnings Top Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 3.32% and 5.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View

TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.

OrganiGram (OGI) Reports Q2 Loss, Tops Revenue Estimates

OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.15%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?

Here is how Eagle Pharmaceuticals (EGRX) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?

Here is how Eagle Pharmaceuticals (EGRX) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

Eagle Pharmaceuticals (EGRX) Lags Q4 Earnings and Revenue Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -2.30% and 10.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

TEVA Stock Up on Q4 Earnings Beat, Sales Miss Estimates

Shares of TEVA rise 8.4% after the company beat earnings estimates despite missing on sales for fourth-quarter 2021. It issues its financial guidance for 2022.

What's in the Cards for Henry Schein (HSIC) in Q4 Earnings?

Solid demand in the global dental market along with an increase in COVID-19 test demand are likely to have contributed to Henry Schein's (HSIC) Q4 performance.

Philips' (PHG) Q4 Earnings Hit By Supply-Chain Issues, Recall

Philips (PHG) fourth-quarter and 2021 results suffer from supply-chain constraints and adverse impact of the Respironics recall.

Zacks.com featured highlights include: Summit Hotel Properties, Meritage Homes, Eagle Pharm and BrightSphere Investment Group

Zacks.com featured highlights include: Summit Hotel Properties, Meritage Homes, Eagle Pharm and BrightSphere Investment Group

Rimmi Singhi headshot

4 High Earnings Yield Stocks Likely to Pay Off Big Time

Summit Hotel (INN), Meritage Homes (MTH), Eagle Pharmaceuticals (EGRX) and BrightSphere (BSIG) could be some attractive bets if you are looking for high earnings yield picks.

Eagle Pharmaceuticals (EGRX) Upgraded to Buy: Here's What You Should Know

Eagle Pharmaceuticals (EGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -35.63% and -14.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Teva's (TEVA) Q3 Earnings and Revenues Miss, Stock Down

Teva Pharmaceutical Industries' (TEVA) shares decline after the company misses both earnings and sales estimates for third-quarter 2021. Meanwhile, it reaffirms its 2021 guidance.

Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Sep 1, 2021

Companies in the news are: NTES, SONN, EGRX, ZEV

Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Surpass Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.68% and 1.74%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TEVA Q2 Earnings Beat Estimates, Revenues Miss, Stock Up

TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view. It expects to settle opioid litigation in the coming year.

New Strong Sell Stocks for June 18th

OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021

Eagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Miss Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -66.67% and -9.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down

TEVA beats on first-quarter earnings and sales. Sales & profits decline year over year. Keeps 2021 view.